A subclinical AK lesion hidden beneath the surface can pose an unseen threat. Photodynamic Therapy offers a field-direct yet targeted approach to help treat visible and subclinical AK lesions.
What is the procedure?
Ameluz® gel is a prescription drug approved by the FDA in combination with the red light BF-RhodoLED®. It is indicated for the lesion-directed and field-directed treatment of Actinic Keratoses (“AK’s”) of mild-to-moderate severity on the face and scalp.
Actinic keratosis is a potential pre-cancerous legion caused by prolonged exposure to the sun and UV rays that come in the form of scaly growths mostly red in color but can be light, dark tan, white, pink/flesh-toned, or a combination of these colors.
How it works
The Ameluz gel combines penetration-promoting nanoemulsion technology with aminolevulinic acid (photosensitizing agents) to improve the delivery of the pharmaceutical ingredients in Ameluz, allowing for rapid tissue penetration. Ameluz is spread in a thick layer on the affected area of the skin and illuminated by the BF-RhodoLED lamp, activating the ingredients in Ameluz and damaging the cells of the actinic keratosis lesions.
During the light treatment, you may experience sensations of burning, tingling, stinging, or prickling of the treated AKs. Following treatment, the AKs and to some degree the surrounding skin may redden, and swelling and scaling may also occur. These effects are temporary and should completely resolve by 2 weeks after treatment. Avoid exposure of your treated skin to sunlight for at least 48 hours.
What is Ameluz®?
Ameluz® is a 10% solution of Aminolevulinic Acid (ALA). ALA is a natural occurring product found in our bodies.
If you are interested in learning more about this treatment or would like to schedule a consult with one of our providers, please contact us here.